Stocks · News reference
Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products
FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
Syringe Filling Machine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031), Syringe Filling Machine Market to Reach USD 2.99 Billion
The global syringe filling machine market is projected to grow from USD 2.09 billion in 2026 to USD 2.99 billion by 2031 at a 7.41% CAGR. Growth is driven by rising demand for prefilled syringes, automated fill-finish lines for biologics, and regulatory focus on aseptic accuracy. Automated systems dominate with 63.92% market share, while servo-driven piston technology leads at 44.05%. Asia-Pacific emerges as the fastest-growing region at 10.72% CAGR, driven by biologics capacity expansion.
B of A Securities Maintains Neutral on Becton Dickinson, Raises Price Target to $200
UBS Maintains Buy on Medline, Lowers Price Target to $43
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.
BTIG Reiterates Buy on Medline, Maintains $55 Price Target
BTIG analyst David Larsen reiterates Medline (NASDAQ:MDLN) with a Buy and maintains $55 price target.